Abstract
In Japan, cancer genomic medicine (GCM) has been started by the approval of cancer gene panel tests covered by the national health insurance system since June 2019. The number of institutes that can perfume cancer gene panel tests has increased from 167 at the beginning to 228 in October 2021, making GCM more accessible. Moreover, FoundationOne®Liquid CDx, which is a type of cancer gene panel test for ctDNA analysis, has been available from August 2021. The environment related to cancer gene panel tests is improving, and GCM opens its door to more and more patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
